Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days). An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.
Official title: Assessment of ECMO in Acute Myocardial Infarction With Non-reversible Cardiogenic Shock to Halt Organ Failure and Reduce Mortality (ANCHOR)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2021-10-14
Completion Date
2027-10-14
Last Updated
2025-01-14
Healthy Volunteers
No
Interventions
VA-ECMO
* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae. * Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France).
Locations (1)
Hôpital Pitié Salpétrière
Paris, France